-
公开(公告)号：NO20032860D0
公开(公告)日：2003-06-20
申请号：NO20032860
申请日：2003-06-20
Applicant: BAXTER INT
Inventor： KIPP JAMES E , WONG JOSEPH CHUNG TAK , DOTY MARK J , REBBECK CHRISTINE L , BRYNJELSEN SEAN , WERLING JANE , SRIRAM RAJARAM
-
公开(公告)号：MXPA02009336A
公开(公告)日：2003-01-28
申请号：MXPA02009336
申请日：2001-03-30
Applicant: BAXTER INT
Inventor： KIPP JAMES E
IPC: A61K9/08 , A61K9/00 , A61K31/34 , A61K31/343 , A61K47/04 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/20 , A61K47/26 , A61P9/06
Abstract: La presente invencion proporciona una solucion parenteral de amiodarona adecuada para la administracion intravenosa sin la necesidad de diluirse. La solucion parenteral tiene una concentracion de amiodarona de 0. 2 a 10 mq/m1 y una solucion amortiguadora seleccionada a partir del grupo que consiste de amortiguador de lactato, amortiguador de matansulfonato o combinaciones de estos, la solucion tiene un pH dentro de la gama de aproximadamente 2.5-4.5.
-
公开(公告)号：CA2431705A1
公开(公告)日：2002-07-18
申请号：CA2431705
申请日：2001-12-20
Applicant: BAXTER INT
Inventor： BRYNJELSEN SEAN , WERLING JANE , REBBECK CHRISTINE L , DOTY MARK J , SRIRAM RAJARAM , KIPP JAMES E , WONG JOSEPH CHUNG TAK
IPC: C07D407/14 , A61K9/10 , A61K9/14 , A61K9/16 , A61K31/495 , A61K31/496 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/24 , A61K47/28 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , A61P31/10 , A61K9/20 , A61K9/51
Abstract: The present invention provides a method for preparing a suspension of a pharmaceutically-active compound, the solubility of which is greater in a water-miscible first organic solvent than in a second solvent which is aqueous. The process includes the steps of : (i) dissolving a first quantity of the pharmaceutically-active compound in the water-miscible first organic solvent to form a first solution ; (ii) mixing the first solution with the second solvent to precipitate the pharmaceutically-active compound ; and (ii i) seeding the first solution or the second solvent or the presuspension.
-
公开(公告)号：AU2351600A
公开(公告)日：2000-06-19
申请号：AU2351600
申请日：1999-12-02
Applicant: BAXTER INT
Inventor： KIPP JAMES E , WEHRMANN GLENN JR , HAMMOND RICHARD B , REBBECK CHRISTINE L
IPC: G01N27/30 , G01N27/416
Abstract: The present invention provides a reference electrode solution containing ammonium salts and phosphonium salts for the potentiometric measurement of pH and method of using the same. The use of the ammonium salts and the phosphonium salts to replace potassium chloride or sodium chloride as reference electrolytes in a standard reference electrode minimizes the formation of precipitates in sample solutions containing cation-sensitive compounds. Disruption of ion flow through the reference electrode is eliminated, and accurate pH measurements may be obtained in solutions that contain compounds having a strong affinity for hard cations.
-
公开(公告)号：BRPI0618661A2
公开(公告)日：2011-09-06
申请号：BRPI0618661
申请日：2006-11-15
Applicant: BAXTER INT , BAXTER HEALTHCARE SA
Inventor： KIPP JAMES E , WERLING JANE , GUPTA PRAMOD , BURESH RITA
IPC: A61K9/14 , A61K9/10 , A61K9/19 , A61K31/38 , A61P1/00 , A61P9/10 , A61P11/06 , A61P17/06 , A61P17/10 , A61P29/00 , A61P35/00 , A61P37/08
Abstract: Pharmaceutical compositions comprising particles of lipoxygenase inhibitor compounds having an effective average size of from about 10 nm to about 50 microns are provided. More particularly, pharmaceutical compositions of particle of a 5-lipoxygenase inhibitor compound having an effective average size of from about 50 nm to about 5 microns are provided. The pharmaceutical compositions are in the form of aqueous suspensions with the particle of the 5-lipoxygenase inhibitor compound present in concentrations of from about 5 to about 200 mg/ml. In addition, methods for making such pharmaceutical compositions are provided. In particular, microprecipitation and direct homogenization in the presence of at least one surfactant are disclosed for making the pharmaceutical compositions.
-
Patent Agency Ranking
公开(公告)号：MX2010012451A
公开(公告)日：2010-12-07
申请号：MX2010012451
申请日：2009-05-08
Applicant: BAXTER INT
Inventor： KIPP JAMES E , RABINOW BARRETT E , WONG JOSEPH C T , NAIR LAKSHMY , MILLER REAGAN
Abstract: Se proporcionan formulaciones farmacéuticas estables y métodos para elaborarlas. En una modalidad general, la presente descripción proporciona un método para elaborar una formulación farmacéutica estable que comprende agregar uno o más aditivos de vitrificación a una solución farmacéutica acuosa para elevar la temperatura de transición al vidrio de la solución farmacéutica acuosa. La solución farmacéutica acuosa puede ser enfriada a una temperatura de aproximadamente -50°C hasta aproximadamente -10°C. El aditivo de vitrificación mejora la formación de un sólido de vidrio o amorfo de la solución farmacéutica acuosa en temperaturas criogénicas (-50°C a - 10°C), y la formulación farmacéutica puede ser descongelada a una forma líquida y administrada a un sujeto mamífero.
-
公开(公告)号：BRPI0517652A
公开(公告)日：2008-10-14
申请号：BRPI0517652
申请日：2005-11-03
Applicant: BAXTER HEALTHCARE SA , BAXTER INT
Inventor： RAAB GERHARD , PAPADOPOULOS PAVLOS , DOTY MARK , KIPP JAMES E , ROESSLER BERTHOLD
IPC: A61K31/404 , A61K9/00 , A61P35/00
Abstract: The present invention is directed to novel pharmaceutical compositions comprising nano- and micro-particulate formulations of poorly water soluble tubulin inhibitors of the indole chemical class, preferably N-substituted indol-3-glyoxyamides, and more preferably N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]glyoxylic acid amide (D-24851), also known as “Indibulin,” and methods of making and using such compositions for the treatment of anti-tumor agent resistant cancers and other diseases.
-
公开(公告)号：AU2006315177A1
公开(公告)日：2007-05-24
申请号：AU2006315177
申请日：2006-11-15
Applicant: BAXTER HEALTHCARE SA , BAXTER INT
Inventor： KIPP JAMES E , BURESH RITA , WERLING JANE , GUPTA PRAMOD
IPC: A61K9/14 , A61K9/10 , A61K9/19 , A61K31/38 , A61P1/00 , A61P9/10 , A61P11/06 , A61P17/06 , A61P17/10 , A61P29/00 , A61P35/00 , A61P37/08
Abstract: Pharmaceutical compositions comprising particles of lipoxygenase inhibitor compounds having an effective average size of from about 10 nm to about 50 microns are provided. More particularly, pharmaceutical compositions of particle of a 5-lipoxygenase inhibitor compound having an effective average size of from about 50 nm to about 5 microns are provided. The pharmaceutical compositions are in the form of aqueous suspensions with the particle of the 5-lipoxygenase inhibitor compound present in concentrations of from about 5 to about 200 mg/ml. In addition, methods for making such pharmaceutical compositions are provided. In particular, microprecipitation and direct homogenization in the presence of at least one surfactant are disclosed for making the pharmaceutical compositions.
-
公开(公告)号：AU2006315169A1
公开(公告)日：2007-05-24
申请号：AU2006315169
申请日：2006-11-15
Applicant: BAXTER HEALTHCARE SA , BAXTER INT
Inventor： GUPTA PRAMOD , KIPP JAMES E
Abstract: The present invention is directed to formulations of inclusion complexes of lipoxygenase inhibitors and cyclodextrins having a therapeutically effective concentration of the lipoxygenase inhibitor, methods of making the same and methods of treating disease states using the same. Forming cyclodextrin complexes permits the enhancement of the aqueous solubility of lipoxygenase inhibitors which allows higher concentrations of the lipoxygenase in solution. Aqueous formulations of lipoxygenase inhibitors-cyclodextrin complexes are suitable for parenteral or oral administration for treating and/or preventing inflammatory disease states. The aqueous formulations can be lyophilized to prolong storage stability, assist in oral administration and/or provide for convenient and economical packaging.
-
公开(公告)号：HU0501030A2
公开(公告)日：2007-02-28
申请号：HU0501030
申请日：2001-12-20
Applicant: BAXTER INT
Inventor： KIPP JAMES E , WONG JOSEPH CHUNG TAK , DOTY MARK J , REBBECK CHRISTINE L , BRYNJELSEN SEAN , WERLING JANE , SRIRAM RAJARAM
-
-
-
-
-
-
-
-
-
Search Results
116
records
(took 0.022 seconds)
